Attenuation of Hepatic Graft-versus-host Disease in Allogeneic Recipients of MyD88-deficient Donor Bone Marrow

Ji-Young Lim¹, Young-Kwan Lee³, Sung-Eun Lee¹, Ji-Min Ju³, Gyeongsin Park², Eun Young Choi³ and Chang-Ki Min¹*

Departments of ¹Internal Medicine, ²Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 137-701, ³Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul 110-799, Korea

Acute graft-versus-host-disease (GVHD) is characterized by selective damage to the liver, the skin, and the gastrointestinal tract. Following allogeneic hematopoietic stem cell transplantation, donor bone marrow (BM) cells repopulate the immune system of the recipient. We previously demonstrated that the acute intestinal GVHD (iGVHD) mortality rate was higher in MyD88-deficient BM recipients than that in the control BM recipients. In the present study, the role of MyD88 (expressed by donor BM) in the pathophysiology of hepatic GVHD (hGVHD) was examined. Unlike iGVHD, transplantation with MyD88-deficient T-cell depleted (TCD) BM attenuated hGVHD severity and was associated with low infiltration of T cells into the liver of the recipients. Moreover, GVHD hosts, transplanted with MyD88-deficient TCD BM, exhibited markedly reduced expansion of CD11b⁺Gr-1⁺ myeloid-derived suppressor cells (MDSC) in the liver. Adoptive injection of the MDSC from wild type mice, but not MyD88-deficient mice, enhanced hepatic T cell infiltration in the MyD88-deficient TCD BM recipients. Pre-treatment of BM donors with LPS increased MDSC levels in the liver of allogeneic wild type BM recipients. In conclusion, hGVHD and iGVHD may occur through various mechanisms based on the presence of MyD88 in the non-T cell compartment of the allograft.

INTRODUCTION

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an important therapeutic modality used to treat malignancies of hematopoietic origin. Graft-versus-host disease (GVHD) is a major complication following allo-HSCT and triggers non-relapse mortality and substantial morbidity. Gastrointestinal tract damage initiated by preconditioning is a principal pathological cause of mortality from GVHD (1), exposing host epithelial and immune cells to products released by dying (eukaryotic) cells and commensal bacteria (LPS and flagellin) and thereby activating TLRs. TLRs are expressed by various cell types, including innate macrophages, dendritic cells, adaptive T and B cells (2), and non-hematopoietic epithelial cells (3). MyD88 is a primary adaptor that mediates TLR signaling and is known to deliver pro-inflammatory signals (4).
However, MyD88 signaling does not always cause inflammation, as demonstrated by the incidence of more severe inflammatory bowel disease in MyD88-deficient mice than that in wild type (WT) mice (5). The recognition of pathogen-derived molecules also occurs through pattern recognition receptors including TLRs, which are widely expressed on parenchymal and nonparenchymal cell types in the liver (6).

Donor bone marrow (BM) cells repopulate the hematopoietic systems of recipients. It was previously reported that MyD88 expression in the allograft non-T cell compartment was important for protection against fatal intestinal GVHD (iGVHD) in two murine models (submitted for publication). To explore the contribution of donor BM MyD88 expression to the development of hepatic GVHD (hGVHD), we induced GVHD using T-cell-depleted (TCD) BM isolated from MyD88-deficient (MyD88KO) donor mice and T cells isolated from WT donors. Here, we observe that the MyD88-dependent expansion of CD11b+ Gr-1+ myeloid derived suppressor cells (MDSC) from donor BM aggravated hGVHD severity with increasing T-cell infiltration into the liver, highlighting the importance of enhanced myeloid cell recovery from donor BM for the development of acute hGVHD.

MATERIALS AND METHODS

Mice
Female C57BL/6 (B6, H-2b), B6.Ly-5a (CD45.1+), and B6D2F1 (F1, H-2b/d) mice were purchased from Japan SLC Inc. (Shizuoka, Japan). MyD88KO (B6, H-2d) mice were generated by Kawai et al. (7) and backcrossed for >10 generations onto the C57BL/6J genetic background. All animal experiments were approved by the institutional Animal Care and Use Committees of the Catholic University and Seoul National University.

Induction of acute GVHD
To generate the MHC- and minor histocompatibility antigen-mismatched transplantation model, F1 mice pre-conditioned with total body irradiation (1,100 cGy) were i.v. injected with TCD BM cells (5×10⁶) plus T cells (1×10⁶ or 2×10⁶) purified from allogeneic B6 mice or B6.Ly-5a (CD45.1+) mice, as previously described (8). For LPS pre-treatment of BM donors, LPS (2 mg/kg body weight) from Escherichia coli (O128-B12; Sigma-Aldrich, St Louis, MO, USA) was i.p. injected daily for 3 days.

Cell isolation and flow cytometric analysis
Mononuclear cells were isolated from liver and peripheral lymph nodes (PLN) as previously described (9). MDSC were purified by magnetic-activated cell sorting after incubation with biotin-conjugated anti-Ly6G, according to the manufacturer’s instructions (Miltenyi Biotec, Auburn, CA, USA). The following antibodies against mouse antigens were purchased from BD Pharmingen (San Diego, CA, USA): FITC-conjugated anti-CD45.1 and anti-CD8; PE-conjugated anti-CD11b and anti-CD4; PerCP-Cy5.5-conjugated anti-CD8; APC-conjugated anti-Ly-6G (Gr-1); and APC-Cy7-conjugated anti-CD4. PE-conjugated anti-β2mb Ab (B10.S) was purchased from Santa Cruz Biotechnology (Dallas, TX, USA).

Histologic and confocal microscopic analyses
Formalin-fixed, paraffin-embedded tissue sections were stained with hematoxylin and eosin. Cryosections were incubated with anti-CD45.1-PE and anti-CD107b-FITC (lysosome-associated membrane protein 2, LAMP2), counterstained with DAPI (Sigma-Aldrich) following washing, and examined under a confocal microscope (LSM700; Carl Zeiss, Oberkochen, Germany).

Serum liver enzymes
An alanine aminotransferase (ALT) kit (Roche, Penzberg, Germany) was used to determine serum concentrations, according to the manufacturer’s instructions.

Statistical analysis
All values are expressed as mean±SEM. Comparisons between the groups were performed using the parametric independent samples t-test if the groups contained more than five animals; otherwise, the Mann-Whitney U-test was used.

RESULTS

Allogeneic recipients of MyD88-deficient donor TCD BM exhibited less severe hepatic damage despite higher mortality
To explore how the absence of MyD88-signaling in donor TCD BM (the non-T cell compartment) affects hGVHD progression, we induced acute GVHD in lethally irradiated F1 mice and then injected T cells purified from WT B6
mice with TCD BM isolated from MyD88KO or WT B6 mice. We have previously demonstrated that allogeneic recipients of MyD88KO TCD BM die of iGVHD earlier than WT B6 TCD BM recipients do (submitted for publication). The GVHD hosts die of severe gastrointestinal damage in this MHC- and minor histocompatibility antigen-mismatched model (1). Unexpectedly, the extent of inflammatory infiltration in the liver was less severe in the MyD88KO TCD BM recipients (Fig. 1A). These findings demonstrated that the lack of MyD88 expression in the non-T cell compartment aggravated the severity of iGVHD in association with serious intestinal damage. In contrast, the presence of MyD88 in the non-T cell compartment exacerbated the severity of hGVHD accompanied by inflammatory infiltration. Consistent with the increased hGVHD-related pathological severity, MyD88KO recipients displayed significantly lower serum ALT levels compared with those of the WT recipients (40.5±3.3 U/L vs. 81.8±10.4 U/L; p < 0.01; n=3−6; Fig. 1B).

Donor T cells heavily infiltrated the livers of allogeneic WT TCD BM recipients

In the allogeneic recipients, irrespective of donor BM origin (i.e., MyD88KO or WT), all of the leukocytes infiltrating the GVHD target organs originated from the donor (data not shown). To more clearly compare the extent of tissue infiltration by donor T cells between the two groups of GVHD hosts, T cells isolated from congenic B6.Ly-5a B6 mice (CD45.1+) were used to induce GVHD. The proportion of CD45.1+ T cells in tissue-infiltrating leukocytes was higher in the livers of MyD88KO TCD BM recipients than that of WT TCD BM recipients, because CD45.1− non-T cell population of the former had much less cells than those of the latter (Fig. 2B). However, the absolute numbers of infiltrating CD45.1+ T cells were lower in MyD88KO TCD BM recipient livers than those of WT TCD BM recipient livers, because the total cellularity levels in the liver were lower in the former (Fig. 2A). Additionally, we quantified CD4+ and CD8+ donor T cell subtype proliferation with respect to the presence of MyD88 in this GVHD model. Differences were evident when the levels of CD8+ cell subtypes were compared with those of CD4+ cells (Fig. 2B, C). Moreover, confocal microscopic analyses revealed that CD45.1+ cells were scarcer in the liver of MyD88KO TCD BM recipients than in WT recipient livers (Fig. 2D).

Reduced expansion of CD11b+Gr-1+ cells in the allogeneic MyD88KO TCD BM recipients

CD45.1− non-T cell compartments, which were notably

Figure 1. Allogeneic recipients of MyD88KO donor TCD-BM exhibit less severe hepatic. Lethally irradiated F1 recipients were given 5×10^5 WT or MyD88KO TCD-BM cells plus 1×10^6 purified WT T cells from allogeneic B6 donors (n=10 in each group, allo WT and allo KO). Control mice were given only TCD-BM from WT or MyD88KO mice (thus without co-transplantation of B6 T cells; n=10 in each group, WT TCD-BM and KO TCD-BM). (A) Liver histology in representative F1 recipients transplanted with WT or MyD88KO TCD-BM plus WT T cells. The extent of mononuclear cell infiltration into portal triads was assessed, and the pathological status was scored semi-quantitatively; 20 portal areas of two liver sections from each animal were evaluated. The areas within the black squares in the ×50 images of the upper panel were magnified to ×200, as shown at the bottoms of the images. The extent of pathological damage to liver was evaluated using the semi-quantitative scoring system described above, in both the allo WT and allo KO groups (n=5 in each group). (B) Serum alanine transaminase (ALT) level. Data are presented as means ± SEMs. Statistics: **p < 0.01 and ***p < 0.001. Data shown are representative of two independent experiments.
Figure 2. Effect of MyD88 deficiency in TCD-BM on the expansion and infiltration of donor-type T cells in liver and peripheral lymph nodes (PLN). Lethally irradiated F1 recipients were given 5×10^6 WT or MyD88KO TCD-BM cells plus 1×10^6 purified WT T cells isolated from congenic B6 donors (CD45.1⁺) (n=5, each group, allo WT and allo KO). (A) The expansion of donor T cells in the liver and PLN were assessed on day 13 post-transplantation. The frequencies and absolute numbers of CD45.1⁺ cells analyzed via flow cytometry are shown. Data are presented as means±SEMs and are representative of duplicate experiments. Statistics: ***p < 0.001. (B and C) The frequencies and numbers of donor-type CD4⁺ (B) and CD8⁺ (C) T cells were examined on day 13. Data are presented as means±SEMs. Statistics: **p < 0.01 and ***p < 0.001. (D) Infiltration of CD45.1⁺ cells in the liver during GVHD. Livers were harvested from F1 recipient mice (n=5) on day 13 and sectioned for staining with anti-CD45.1 Ab as described in “Materials and Methods”. Magnification: ×50 (upper) and ×100 (lower). Data from one of two replicate experiments that yielded similar results are shown.
Effect of Bone Marrow MyD88 Signaling in Hepatic GVHD
Ji-Young Lim, et al.

Figure 3. Effect of MyD88 deficiency in TCD-BM on the expansion of CD11b+Gr-1+ MDSC. Lethally irradiated F1 recipients were given 5×10⁶ WT or MyD88KO TCD-BM cells plus 1×10⁶ purified WT T cells isolated from WT B6 donors (n=5, each group, allo WT and allo KO). (A) On day 13 thereafter, the liver and peripheral lymph nodes (PLN) were harvested and the expression levels of CD11b+Gr-1 were measured via flow cytometric analysis. The proportions and absolute numbers of CD11b+Gr-1 cells are shown. Data are presented as means ± SEMs and are representative of duplicate experiments. Statistics: ***p < 0.001. (B) Peripheral blood mononuclear cells (PBMC) from GVHD hosts that received WT or MyD88KO TCD-BM (n=3 in each group, allo WT and allo KO, respectively) were stained with anti-LAMP2 antibody. The numbers of LAMP2-positive neutrophils in immunofluorescence fields were compared between the allo WT and allo KO groups. The data shown are representative of two independent experiments.

Supplementation of MyD88KO TCD BM recipients with WT MDSC enhanced donor T-cell infiltration into the liver
Next, we explored whether supplementation of GVHD hosts with WT MDSC during the course of GVHD could compensate for the lack of MDSC expansion and increase T cell infiltration into the livers of the MyD88KO TCD BM recipients. To this end, MDSC (1×10⁶) purified from WT or MyD88 KO BM were injected on days 3, 5, and 7 post-transplantation into GVHD hosts that had received MyD88KO TCD BM. WT MDSC supplementation increased hepatic T-cell number in the MyD88KO TCD BM recipients. In contrast, enhanced donor T cell infiltration into the liver was not observed following supplementation with MyD88KO MDSC (Fig. 4A). CD4+ and CD8+ T cell numbers were also enhanced in the livers of MyD88KO TCD BM recipients following supplementation with WT MDSC compared with those of animals supplemented with MyD88KO MDSC (Fig. 4B, C). In addition, the number

rare in the MyD88KO TCD BM recipient organs analyzed (Fig. 2A), were comprised primarily of CD11b+Gr-1+ cells (Fig. 3A). The low proportion of CD11b+Gr-1+ cells in the MyD88KO group was attributed to the low levels of expansion from transplanted MyD88KO TCD BM in response to pro-inflammatory stimuli produced in the GVHD hosts. This is because the proportions of CD11b+Gr-1+ cells in naïve BM and in different peripheral organs of MyD88KO mice (i.e., prior to transplantation) were comparable to those of WT B6 mice (data not shown). However, the numbers of LAMP2+ neutrophils did not differ significantly between the two groups (Fig. 3B), indicating intact generation of neutrophils in the MyD88KO TCD BM recipients. Therefore, the reduced number of CD11b+Gr-1+ MDSC from MyD88KO BM was associated with reduced T-cell infiltration into the liver, which suggested the possibility that MDSC could enhance T cell infiltration into the liver (Fig. 2B).
Figure 4. Injection of CD11b<sup>+</sup> Gr-1<sup>+</sup> MDSC from WT mice, but not MyD88KO mice, enhances donor T-cell infiltration into the livers. Lethally irradiated F1 recipients were given 5×10<sup>6</sup> MyD88KO TCD-BM cells plus 1×10<sup>6</sup> purified WT T cells from allogeneic B6 donors. Mice exhibiting GVHD that had received MyD88KO TCD-BM cells were injected with 1.0×10<sup>6</sup> CD11b<sup>+</sup> Gr-1<sup>+</sup> MDSC isolated from WT or MyD88KO mice at days 3, 5, and 7 post-transplantation. (A ∼ D) The frequencies and absolute numbers of donor T cells (A) with donor-type CD4<sup>+</sup> (B) and CD8<sup>+</sup> (C) T cells analyzed via flow cytometry are shown. (D) Expression of CD11b<sup>+</sup> Gr-1<sup>+</sup> was measured using FACS analysis. The frequencies and absolute numbers of CD11b<sup>+</sup> Gr-1<sup>+</sup> cells are shown. Data are presented as means±SEMs. Statistics: *p < 0.05, **p < 0.01 and ***p < 0.001. Data are representative of duplicate experiments (n=6 per experiment).
Figure 5. Recipients of TCD BM from WT donor mice injected with LPS show high MDSC levels in the liver with decreased frequency of donor T cells. WT or MyD88KO B6 donor mice were subjected to i.p. injection of LPS at 2 mg/kg for 3 days. Mice not receiving LPS received an equal amount of the LPS vehicle (PBS i.p.). Lethally irradiated F1 recipients were given 5×10⁶ LPS- or PBS-treated donor TCD-BM cells plus 1×10⁶ purified WT T cells from allogeneic B6 donors (n=6 per group). (A–D) The frequencies and absolute numbers of donor T cells (A), and donor-type CD4⁺ (B) and CD8⁺ (C) T cells analyzed via flow cytometry are shown. (D) The expression levels of CD11b⁺ Gr-1⁺ were measured via FACS. The frequencies and absolute numbers of CD11b⁺ Gr-1⁺ cells are shown. The data are presented as means± SEMs. Statistics: **p < 0.01 and ***p < 0.001. Data are representative of duplicate experiments.
of MDSC increased in the liver following WT MDSC supplementation (Fig 4D). WT MDSC supplementation into the recipients of MyD88KO TCD BM showed more efficient recruitment of donor T cells into livers than MyD88-deficient MDSCs, supporting the idea that MyD88 deficiency in donor BM not only blunted MDSC recruitment or expansion in liver, but also led to generation of MDSC functionally defective in recruiting donor T cells into the liver. These results indicated that functionally intact WT MDSC have a better capability for recruiting or expanding donor T cells than MyD88-deficient MDSC and increase hGVHD incidence.

LPS-injected WT TCD BM recipients displayed high MDSC levels accompanied by a decreased frequency of donor T cells in the liver

To verify the importance of MyD88-mediated signaling by MDSC in the induction of hGVHD, we determined whether transplantation with TCD BM cells containing high levels of MDSC exacerbates hGVHD. As repeated injection of LPS elicits the development of MDSC (10), we injected BM donors with LPS prior to the preparation of TCD BM and confirmed that such pre-treatment increased MDSC frequency and MyD88 expression in the TCD BM inoculums (data not shown). Transplantation with TCD BM isolated from LPS-pre-treated donors significantly decreased the frequency of CD45.1^+^, CD4^+^, and CD8^+^ T cells in the livers compared with that following vehicle-pre-treated TCD BM transplantation (Fig. 5A∼C). There was a trend toward an increase in the absolute number of CD45.1^+^, CD4^+^, and CD8^+^ T cells following transplantation with TCD BM injected LPS as compared with that after transplantation with control TCD BM that had been pre-treated with the vehicle even if the statistical significance of this increase was not observed. The proportions and number of MDSC in the livers were higher (Fig. 5D) in the test recipients than those in controls.

DISCUSSION

Following allo-HSCT, donor-derived BM cells repopulate the hematopoietic systems of recipients but may also participate in GVHD pathogenesis, because donor APC co-present host antigens to alloreactive donor T cells and exacerbate GVHD (11). However, with the exception of donor APC and T cells, such roles for donor-derived immune cells in hGVHD pathogenesis, have rarely been reported. In the present study, we observed that expression of MyD88 in the non-T cell component of the donor allograft (TCD BM) was important for the induction of hGVHD in a murine model. Lack of MyD88 expression in the TCD BM transplant caused incomplete expansion of MDSC and reduced donor T cell infiltration in allogeneic recipient livers. In addition, an increase in MDSC frequency and MyD88 levels in the TCD BM (achieved via pre-treatment of donors with LPS) enhanced MDSC expansion in the livers.

Inflammation is a key component of a wide range of liver diseases, including hGVHD, steatohepatitis, and acute liver failure due to systemic infections. Of the 10 human TLRs in humans, all are expressed in the liver at the mRNA level, and functional activity of most TLRs was found in the various parenchymal and nonparenchymal liver cell populations (6,12). It has been demonstrated that expression of the pathogen-sensing machinery in immune cells is important for liver sensitization. In chimera mice that received Propionibacterium acnes or TLR2 and TLR9 ligand treatment to induce liver sensitization, BM-derived immune cells contributed to the damage of the sensitized liver in response to endotoxin (13). In patients with hGVHD, liver biopsies reveal lymphocytic infiltration of small bile ducts with nuclear pleomorphism, epithelial cell dropout, and cholestasis in zone 3 of the liver acinus (14). Our study demonstrated that the extent of inflammatory infiltration was less severe in the MyD88KO TCD BM recipients that had inappropriate BM-derived immune cells, and the appropriate expansion of donor hematopoietic cells might be involved in the hepatic injury observed in hGVHD pathogenesis. A primary effect of MyD88-signaling in hGVHD may be aggravated inflammation via MDSC expansion, whereas the extent of MDSC expansion was reduced in MyD88-deficient mice following cecal ligation and puncture in a model of sepsis (15). In addition, MyD88-deficient mice developed more severe intestinal inflammation than the WT animals in an experimental model of inflammatory bowel disease (5), emphasizing the importance of MyD88-signaling in the protection of the host from the development of several inflammatory diseases involving the intestines.

There is a link between the immunosuppressive properties of MDSC and the extent of GVHD protection following experimental allo-HSCT (16,17). MDSC, derived from embryonic stem cells (18) or generated ex vivo by IL-13
treatment (19), reduced the lethality of GVHD. Wang et al. (16), however, observed that injection of immature BM MDSC did not exert such suppressive effects. Therefore, it is probable that both pro-inflammatory and regulatory effects are exerted by MyD88-mediated signaling during the development of GVHD pathophysiology, and that these effects are cell type-specific. Thus, any protective role exerted by MyD88 may be associated with MDSC expansion in the context of GVHD, whereas the pro-inflammatory role may occur primarily in hepatic cells.

In conclusion, our results demonstrate that MyD88-dependent CD11b+Gr-1+ MDSC expansion may be associated with inflammatory cell recruitment and liver injury following transplantation. Selective MyD88 deficiency in hematopoiesis from donor TCD BM could be critical for the early induction of hGVHD following allo-HSCT, providing useful information regarding the development of target organ specificity.

ACKNOWLEDGEMENTS

This study was supported by the Korea Healthcare Technology R&D Project, Ministry of Health, Welfare, and Family Affairs, Republic of Korea (Grant no. A120262).

CONFLICTS OF INTEREST

The authors have no financial conflict of interest.

REFERENCES

1. Hill, G. R., J. M. Crawford, K. R. Cooke, Y. S. Brinson, L. Pan, and J. L. Ferrara. 1997. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 90: 3204-3213.
2. Caron, G., D. Duluc, I. Fremaux, P. Jeannin, C. David, H. Gascan, and Y. Dehneste. 2005. Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells. J. Immunol. 175: 1551-1557.
3. Heimesaat, M. M., A. Nogai, S. Bereswill, P. Plickert, A. Fischer, C. Loddenkemper, U. Steinhoff, S. Teichpecht, E. Thiel, M. A. Freudenberg, U. B. Gobel, and L. Uharek. 2010. MyD88/TLR9 mediated immunopathology and gut microbiota dynamics in a novel murine model of intestinal graft-versus-host disease. Gut 59: 1079-1087.
4. Quigley, M., J. Martinez, X. Huang, and Y. Yang. 2009. A critical role for direct TLR2-MyD88 signaling in CD8+ T-cell clonal expansion and memory formation following vaccinia viral infection. Blood 113: 2256-2264.
5. Rakoff-Nahoum, S., J. Paglino, F. Eslamis-Varzaneh, S. Edberg, and R. Medzhitov. 2004. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118: 229-241.
6. Szabo, G., A. Dolganiuc, and P. Mandrekar. 2006. Pattern recognition receptors: a contemporary view on liver diseases. Hepatology 44: 287-298.
7. Kawai, T., O. Adachi, T. Ogawa, K. Takeda, and S. Akira. 1999. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11: 115-122.
8. Min, C. K., Y. Maeda, K. Lowner, C. Liu, S. Clouthier, D. Loftus, E. Weisiger, J. L. Ferrara, and P. Reddy. 2004. Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation. Blood 104: 3393-3399.
9. Comer, G. M., W. G. Ramey, D. P. Kotler, and P. R. Holt. 1986. Isolation of intestinal mononuclear cells from colonscopic biopsies for immunofluorescence analysis by flow cytometry. Dig. Dis. Sci. 31: 151-156.
10. De, W., V. R. N. Van, M. Hill, J. F. Lebrun, P. Lemaître, F. Lhomme, C. Kuhjak, B. Vokaer, G. Oldenhove, L. M. Charbonnier, M. C. Caturi, M. Goldman, and M. A. Le. 2009. Endotoxin-in-induced myeloid-derived suppressor cells inhibit alloimmune responses via heme oxygenase-1. Am. J. Transplant. 9: 2034-2047.
11. Matte, C. C., J. Liu, J. Cormier, B. E. Anderson, I. Athanasiadis, D. Jain, J. McNiff, and W. D. Silichni. 2004. Donor APCs are required for maximal GVHD but not for GVL. Nat. Med. 10: 987-992.
12. Zarember, K. A., and P. J. Godowski. 2002. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J. Immunol. 168: 554-561.
13. Hritz, I., A. Velayudham, A. Dolganiuc, K. Kodys, P. Mandrekar, E. Kurt-Jones, and G. Szabo. 2008. Bone marrow-derived immune cells mediate sensitization to liver injury in a myeloid differentiation factor 88-dependent fashion. J. Immunol. 180: 3204-3213.
14. Shulman, H. M., P. Sharma, D. Amos, L. F. Fenster, and G. B. McDonald. 1988. A coded histologic study of hepatic graft-versus-host disease after human bone marrow transplantation. Hepatology 8: 463-470.
15. Delano, M. J., P. O. Scumpia, J. S. Weinstein, D. Coco, S. Nagaraj, K. M. Kelly-Scumpia, K. A. O'Malley, J. L. Wyns, S. Antonenko, S. Z. Al-Qarun, R. Swan, C. S. Chang, M. A. Atkinson, R. Ramphal, D. I. Gabrilovich, W. H. Reeves, A. Ayala, J. Phillips, D. Lafface, P. G. Heyworth, M. Clare-Salzler, and L. L. Moldawer. 2007. MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and TH2 polarization in sepsis. J. Exp. Med. 204: 1463-1474.
16. Wang, D., Y. Yu, K. Haarberg, J. Fu, K. Kaosaard, S. Nagaraj, C. Anasetti, D. Gabrilovich, and Z. X. Yu. 2013. Dynamic change and impact of myeloid-derived suppressor cells in allogeneic bone marrow transplantation in mice. Biol. Blood Marrow Transplant. 19: 692-702.
17. Ghansah, T., K. H. Paraiso, S. Highfill, C. Desponts, S. May, J. K. McIntosh, J. W. Wang, J. Ninos, J. Brayer, F. Cheng, E.
Sotomayor, and W. G. Kerr. 2004. Expansion of myeloid suppressor cells in SHIP-deficient mice represses allogeneic T cell responses. *J. Immunol.* 173: 7324-7330.

18. Zhou, Z., D. L. French, G. Ma, S. Eisenstein, Y. Chen, C. M. Divino, G. Keller, S. H. Chen, and P. Y. Pan. 2010. Development and function of myeloid-derived suppressor cells generated from mouse embryonic and hematopoietic stem cells. *Stem Cells* 28: 620-632.

19. Highfill, S. L., P. C. Rodriguez, Q. Zhou, C. A. Goetz, B. H. Koehn, R. Veenstra, P. A. Taylor, A. Panoskaltsis-Mortari, J. S. Serody, D. H. Munn, J. Tolar, A. C. Ochoa, and B. R. Blazar. 2010. Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. *Blood* 116: 5738-5747.